<DOC>
	<DOC>NCT00444795</DOC>
	<brief_summary>To monitor use in real practice including adverse events and efficacy on Sutent capsules (Sunitinib malate)</brief_summary>
	<brief_title>Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutene</brief_title>
	<detailed_description>All the patients prescribed according to approved indications at contracted institutions</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Patients diagnosed as gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate, or advanced renal cell carcinoma (aRCC) will be included in the study, or patients diagnosed as unresectable, welldifferentiated advanced and/or metastatic pancreatic neuroendocrine carcinoma. Any patient who does not agree that Pfizer and companies working with Pfizer use his/her information will be excluded. Patients with hypersensitivity to sunitinib malate or to any other component of Sutent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>SUTENE</keyword>
	<keyword>post-marketing surveillance</keyword>
	<keyword>GIST</keyword>
	<keyword>RCC</keyword>
	<keyword>Korea</keyword>
</DOC>